EE288 Decision Model to Evaluate the Cost of Clinical Events Associated with Switching from Apixaban to Rivaroxaban Among Patients with Non-Valvular Atrial Fibrillation in Germany
Abstract
Authors
R Subash A Shah C Duan D Hines M Zhang M Hagan